|
43 Companies |
|
40 Products |
|
40 Products |
|
30 Mechanisms of Action |
|
1 Trial |
|
293 News |
|
| «1234567» |
- ||||| Naftin (naftifine hydrochloride) / Merz Pharma
New P4 trial: Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis (clinicaltrials.gov) - Oct 21, 2012
P4, N=65, Completed, Sponsor: Merz Pharmaceuticals, LLC
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Observational data, Adverse events, Serious adverse event: The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=35, Completed, Sponsor: University Hospital, Toulouse
Recruiting --> Completed
- New P2 trial: Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years (clinicaltrials.gov) - Sep 27, 2012
P2, N=42, Completed, Sponsor: Quinnova Pharmaceuticals, Inc.
- ||||||| Trial completion: Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis (clinicaltrials.gov) - Sep 26, 2012
P3, N=336, Completed, Sponsor: AmDerma
Recruiting --> Completed Recruiting --> Completed
- Promacta (eltrombopag) / Novartis
Enrollment open: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (clinicaltrials.gov) - Sep 24, 2012
P2, N=26, Recruiting, Sponsor: Fondazione Progetto Ematologia
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Trial completion: Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis (clinicaltrials.gov) - Sep 23, 2012
P3, N=264, Completed, Sponsor: AmDerma
Not yet recruiting --> Recruiting Recruiting --> Completed
- sirolimus / Generic mfg.
Clinical: Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Aug 22, 2012
P=N/A, N=35, Completed, Sponsor: First Affiliated Hospital of Suzhou Medical College
- Clinical: Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Aug 16, 2012
P=N/A, N=35, Completed, Sponsor: First Affiliated Hospital of Suzhou Medical College
- | danazol oral / Generic mfg.
New P2 trial: The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia (clinicaltrials.gov) - Aug 15, 2012
P2, N=80, Active, not recruiting, Sponsor: Peking University People's Hospital
- | Doptelet (avatrombopag) / SOBI
Trial completion: A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 (clinicaltrials.gov) - Aug 12, 2012
P1, N=28, Completed, Sponsor: Eisai Inc.
Recruiting --> Completed Recruiting --> Completed
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. (clinicaltrials.gov) - Aug 7, 2012
P2, N=124, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- Clinical data, Trial completion: Effect of Timing of Umbilical Cord Clamping on Haematological and Clinical Outcomes of Infants (clinicaltrials.gov) - Jul 31, 2012
P2, N=340, Completed, Sponsor: Aga Khan University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Promacta (eltrombopag) / Novartis
New P2 trial: Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT (clinicaltrials.gov) - Jul 26, 2012
P2, N=30, Completed, Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
- New P4 trial: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome (clinicaltrials.gov) - Jun 18, 2012
P4, N=16, Recruiting, Sponsor: Vanderbilt University
- New P3 trial: Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction (clinicaltrials.gov) - Jun 17, 2012
P3, N=40, Recruiting, Sponsor: Samsung Medical Center
- ||| Privigen (human immune globulin intravenous 10%) / CSL Behring
Preclinical, Trial initiation date: A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Jun 2, 2012
P4, N=150, Recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed Initiation date: Jul 2011 --> Nov 2011
- |||||||||| blisibimod (A-623) / Anthera Pharma
New P2/3 trial: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) - May 30, 2012
P2/3, N=60, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
- Promacta (eltrombopag) / Novartis
New P2 trial: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (clinicaltrials.gov) - May 30, 2012
P2, N=26, Recruiting, Sponsor: Fondazione Progetto Ematologia
- | Trial completion: Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults (clinicaltrials.gov) - May 28, 2012
P2, N=17, Completed, Sponsor: Oculus Innovative Sciences, Inc.
Initiation date: Jul 2011 --> Nov 2011 Recruiting --> Completed
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 28, 2012
P2, N=60, Completed, Sponsor: Hamilton Health Sciences Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- REGN846 / Regeneron
New P1/2 trial: Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis (clinicaltrials.gov) - May 23, 2012
P1/2, N=19, Terminated, Sponsor: Regeneron Pharmaceuticals
- | Doptelet (avatrombopag) / SOBI
Trial completion: Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. (clinicaltrials.gov) - May 17, 2012
P1, N=36, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Promacta (eltrombopag) / Novartis
Enrollment closed: A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 16, 2012
P4, N=150, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment open: Vulvar Contact Dermatitis Resulting From Urine Incontinence (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=400, Recruiting, Sponsor: Meir Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Promacta (eltrombopag) / Novartis
Trial completion: PLATEFUN: Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag (clinicaltrials.gov) - Apr 18, 2012
P4, N=30, Completed, Sponsor: Ingrid Pabinger, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment open: Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates (clinicaltrials.gov) - Apr 17, 2012
P1/2, N=616, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| New P3 trial: Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis (clinicaltrials.gov) - Apr 17, 2012
P3, N=1053, Completed, Sponsor: Taro Pharmaceuticals USA
- ||| clotrimazole topical / Generic mfg.
New P1 trial: Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra (clinicaltrials.gov) - Apr 17, 2012
P1, N=707, Completed, Sponsor: Taro Pharmaceuticals USA
- Trial completion: Effect of Weight Loss on Psoriasis (clinicaltrials.gov) - Apr 2, 2012
P=N/A, N=60, Completed, Sponsor: University Hospital, Gentofte, Copenhagen
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change: Association of Thyroid Autoimmunity and Chronic Urticaria (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=155, Completed, Sponsor: Far Eastern Memorial Hospital
Active, not recruiting --> Completed N=100 --> 155
- morphine sulphate / Generic mfg.
Trial completion: Efficacy of Acupuncture for Prophylaxis of Intrathecal Morphine Induced Pruritis in Patients Undergoing Caesarean Delivery (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=44, Completed, Sponsor: Letterkenny General Hospital
N=100 --> 155 Recruiting --> Completed
- Trial completion: Association of Thyroid Autoimmunity and Chronic Urticaria (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=155, Completed, Sponsor: Far Eastern Memorial Hospital
Recruiting --> Completed Recruiting --> Completed
- ||||||| Trial completion: Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis (clinicaltrials.gov) - Mar 13, 2012
P3, N=290, Completed, Sponsor: Novartis
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Doptelet (avatrombopag) / SOBI
Trial completion: Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects (clinicaltrials.gov) - Mar 7, 2012
P1, N=84, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- | Doptelet (avatrombopag) / SOBI
New P1 trial: A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 (clinicaltrials.gov) - Mar 6, 2012
P1, N=28, Completed, Sponsor: Eisai Inc.
- Trial completion: CRN11: A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients (clinicaltrials.gov) - Feb 23, 2012
P4, N=50, Completed, Sponsor: Winthrop University Hospital
Recruiting --> Completed Enrolling by invitation --> Completed
- Promacta (eltrombopag) / Novartis
Enrollment open: Promacta Pregnancy Registry (clinicaltrials.gov) - Feb 19, 2012
P=N/A, N=1, Recruiting, Sponsor: GlaxoSmithKline
Enrolling by invitation --> Completed Active, not recruiting --> Recruiting
- Enrollment closed: TcBili: Transcutaneous Measurement of Jaundice in the Newborn (clinicaltrials.gov) - Feb 11, 2012
P=N/A, N=1500, Active, not recruiting, Sponsor: Norwegian University of Science and Technology
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial, Combination therapy: rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP (clinicaltrials.gov) - Feb 1, 2012
P3, N=240, Recruiting, Sponsor: Shandong University
- New P3 trial: Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis (clinicaltrials.gov) - Jan 31, 2012
P3, N=42, Completed, Sponsor: Prof. Yuen Chun-Wah
- |||||||||| Promacta (eltrombopag) / Novartis
New P3 trial: PETIT2: Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (clinicaltrials.gov) - Jan 26, 2012
P3, N=92, Completed, Sponsor: GlaxoSmithKline
- ||||| Promacta (eltrombopag) / Novartis
Enrollment change: EXTEND (Eltrombopag Extended Dosing Study) (clinicaltrials.gov) - Jan 25, 2012
P3, N=302, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting N=400 --> 302
- ||| New P1 trial: A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis (clinicaltrials.gov) - Jan 25, 2012
P1, N=661, Completed, Sponsor: Taro Pharmaceuticals USA
- ||||||| Naftin (naftifine hydrochloride) / Merz Pharma
Trial completion: Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis (clinicaltrials.gov) - Jan 22, 2012
P3, N=860, Completed, Sponsor: Merz Pharmaceuticals, LLC
N=400 --> 302 Recruiting --> Completed
- ||||||| Naftin (naftifine hydrochloride) / Merz Pharma
Trial completion: Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis (clinicaltrials.gov) - Jan 22, 2012
P3, N=855, Completed, Sponsor: Merz Pharmaceuticals, LLC
Recruiting --> Completed Recruiting --> Completed
- |||| Privigen (human immune globulin intravenous 10%) / CSL Behring
Enrollment open, Preclinical: A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Jan 17, 2012
P4, N=150, Recruiting, Sponsor: CSL Behring
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Trial completion: Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Dec 30, 2011
P2, N=61, Completed, Sponsor: Symphogen A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Clinical: Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct (clinicaltrials.gov) - Dec 22, 2011
P=N/A, N=110, Recruiting, Sponsor: Institut Paoli-Calmettes
- |||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment open: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Dec 12, 2011
P3, N=60, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Enrollment change: Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC) (clinicaltrials.gov) - Nov 15, 2011
P2, N=122, Completed, Sponsor: Taisho Pharmaceutical R&D Inc.
Not yet recruiting --> Recruiting N=240 --> 122